Altimmune Inc (ALT)
7.19
+0.12
(+1.70%)
USD |
NASDAQ |
May 02, 16:00
6.99
-0.20
(-2.78%)
After-Hours: 20:00
Altimmune Revenue (TTM): 0.426M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.426M |
| September 30, 2023 | 0.279M |
| June 30, 2023 | -0.081M |
| March 31, 2023 | -0.079M |
| December 31, 2022 | -0.068M |
| September 30, 2022 | 3.319M |
| June 30, 2022 | 3.475M |
| March 31, 2022 | 3.604M |
| December 31, 2021 | 4.41M |
| September 30, 2021 | 3.446M |
| June 30, 2021 | 6.226M |
| March 31, 2021 | 6.810M |
| December 31, 2020 | 8.185M |
| September 30, 2020 | 6.448M |
| June 30, 2020 | 4.154M |
| March 31, 2020 | 5.058M |
| December 31, 2019 | 5.801M |
| September 30, 2019 | 7.814M |
| June 30, 2019 | 9.805M |
| March 31, 2019 | 10.60M |
| December 31, 2018 | 10.33M |
| September 30, 2018 | 18.44M |
| June 30, 2018 | 15.84M |
| March 31, 2018 | 13.42M |
| December 31, 2017 | 10.74M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.2783M |
| June 30, 2017 | 0.2566M |
| March 31, 2017 | 0.4101M |
| December 31, 2016 | 1.411M |
| September 30, 2016 | 2.436M |
| June 30, 2016 | 3.586M |
| March 31, 2016 | 4.578M |
| December 31, 2015 | 10.64M |
| September 30, 2015 | 11.20M |
| June 30, 2015 | 11.01M |
| March 31, 2015 | 13.52M |
| December 31, 2014 | 10.19M |
| September 30, 2014 | 12.02M |
| June 30, 2014 | 14.54M |
| March 31, 2014 | 15.18M |
| December 31, 2013 | 17.91M |
| September 30, 2013 | 20.27M |
| June 30, 2013 | 23.48M |
| March 31, 2013 | 25.50M |
| December 31, 2012 | 25.18M |
| September 30, 2012 | 25.40M |
| June 30, 2012 | 23.97M |
| March 31, 2012 | 24.08M |
| December 31, 2011 | 24.27M |
| September 30, 2011 | 24.88M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
-0.081M
Minimum
Jun 2023
9.805M
Maximum
Jun 2019
4.160M
Average
4.154M
Median
Jun 2020
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 35.93B |
| Amgen Inc | 28.19B |
| Pfizer Inc | 58.50B |
| Viking Therapeutics Inc | -- |
| Precision BioSciences Inc | 48.73M |